Skip to content
Review Open access

EFFICACY OF ORAL NIFEDIPINE VERSUS LABETALOL IN THE EMERGENCY MANAGEMENT OF HYPERTENSIVE CRISIS IN PREGNANCY: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS AND PRIMARY STUDIES

Nov 2026 · International journal of medical science and health research · Vol 49, pp. 1422-1508 · 0 citations

TL;DR

Oral nifedipine controls hypertensive crisis significantly faster with fewer doses than labetalol, with a moderate discriminative advantage (AUC 0.668) and equivalent maternal/perinatal safety in randomized evidence.

Abstract

Introduction: Hypertensive disorders complicate one in ten pregnancies and remain leading causes of maternal mortality worldwide. Severe hypertension (SBP ≥160 mmHg and/or DBP ≥110 mmHg) constitutes an obstetric emergency due to imminent risks of intracerebral hemorrhage, eclampsia, pulmonary edema, and placental abruption. Oral nifedipine and labetalol are the most widely used first-line agents, yet comparative evidence remains fragmented. This review aimed to determine whether oral nifedipine differs from labetalol in acute control of hypertensive crisis in pregnancy across fifteen pre-specified clinical outcomes. Methods: A systematic review was conducted per PRISMA 2020 guidelines. Eligible designs included RCTs, quasi-experimental trials, prospective/retrospective cohorts, case-control, and cross-sectional studies comparing nifedipine with labetalol in pregnant women with severe hypertension. Risk of bias was appraised with Cochrane RoB 2 and ROBINS-I; certainty with GRADE. A binormal ROC reconstruction was performed for time-to-target blood pressure, with AUC representing probability of earlier attainment. Results: Twenty-one primary studies (15 RCTs, 1 quasi-experimental, 2 prospective cohorts, 3 retrospective cohorts) comprising ≥9,889 pregnant women from ten countries were included. Oral nifedipine reached target BP significantly faster than labetalol: pooled MD -9.10 minutes (95% CI -13.69 to -4.51; τ²=11.55; I²=44.2%). Reconstructed pooled AUC was 0.668 (95% CI 0.609-0.727; I²=0.0%), significantly exceeding 0.500. Nifedipine required fewer doses, produced greater systolic/diastolic reduction, and increased urine output. Maternal/perinatal adverse events, caesarean delivery, fetal heart-rate abnormality, Apgar<7, and NICU admission did not differ significantly. One large observational cohort favored labetalol for composite maternal morbidity (aRR 1.33, 95% CI 1.07-1.64). Risk of bias was low in 5/15 RCTs, moderate-to-serious in all non-randomized studies. GRADE certainty was moderate for time-to-target and dose requirement, low/very low for patient-important outcomes. Discussion: Nifedipine's pharmacodynamic superiority in speed and dose economy is consistent, mechanistically coherent, and reproducible. However, speed is a surrogate outcome; the largest observational dataset raises signals of increased eclampsia, HELLP, and renal failure with nifedipine. The AUC of 0.668 quantifies the advantage as modest—statistically significant but far from the >0.80 threshold justifying categorical protocol change. Conclusion: Oral nifedipine controls hypertensive crisis significantly faster with fewer doses than labetalol, with a moderate discriminative advantage (AUC 0.668) and equivalent maternal/perinatal safety in randomized evidence. Requiring no IV access, infusion pump, or continuous cardiotocography, nifedipine should be regarded as a legitimate first-line option—and in resource-constrained settings, the preferred option.

Read PDF

Similar papers

Sep 2026

Comparison of oral enalapril-hydrochlorothiazide and oral nifedipine in treating postpartum hypertension: An open label randomised controlled trial.

BACKGROUND Postpartum hypertension is a common complication following hypertensive disorders of pregnancy and is associated with increased short- and long-term cardiovascular risk. Evidence guiding optimal oral antihypertensive therapy in the postpartum period remains limited. OBJECTIVE To compare the efficacy and sa...

Raveena Bhagat, Sangam Jha, Supriya Subhi · 0 citations
Review

Oral antihypertensive agents in pregnancy

Hypertensive disorders of pregnancy (HDP) affect up to 10% of pregnancies worldwide and represent a primary cause of maternal and perinatal morbidity and mortality, giving rise to acute maternal complications such as HELLP syndrome and eclampsia, as well as fetal growth restriction (FGR) and preterm birth. To manage ma...

R. J. Hup · 0 citations
Review Nov 2026

Nicardipine for the Treatment of Severe Hypertension in Pregnancy: An Updated Review.

IMPORTANCE To reduce morbidity (and mortality) due to severe hypertension in pregnancy by searching the most effective and safe treatment. OBJECTIVE Update of our review (2010) on efficacy and safety of intravenous nicardipine for treatment of severe hypertension in pregnancy. EVIDENCE ACQUISITION Articles were ide...

Sebastiaan W. A. Nij Bijvank Md, Johannes J. Duvekot Md · 0 citations
Nov 2026

Comment on “Prophylactic Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Women With Placenta Previa: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial”

Placenta previa increases the risk of postpartum hemorrhage (PPH), which has been associated with >20% of maternal deaths worldwide. In China, the prevalence of placenta previa increased 3-fold after the universal two-child policy was implemented. Tranexamic acid (TXA) has been used to treat PPH during cesarean deliver...

Aaron B. Caughey · 0 citations
Meta-analysis Open access Sep 2026

Efficacy and safety of zilebesiran in adults with hypertension: a systematic review and meta-analysis of randomized controlled trials

Overall, zilebesiran produced significant and consistent BP reductions, especially in ambulatory measures, with a favorable safety profile, and builds on previous meta-analyses that included only 2 RCTs; this updated analysis reflects the need for novel therapeutic options.

Muhammad Hussain, Muhammad Hassan, Asharib Sohaib et al. · 2 citations
Review Open access Oct 2026

Early Initiation of Dapagliflozin in Acute Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Highlights What are the main findings? Early dapagliflozin initiation significantly reduced all-cause mortality but not heart failure hospitalization in the all-population analysis. Initiation of dapagliflozin was associated with a significant reduction in urinary tract infections (UTIs), without an increase in any adv...

Abdullah Almaqhawi, Ahmed K. Alsaif, Hamza Ashraf et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.